CytoDyn Inc.Long
CYDY correction baked w/5 micros down in 4.25-4.45 region.
CYDY has completed 5 micro waves down from i 6.8 area to ii 4.4 area. This should be launching point towards teens from next week's topline efficacy report for Phase II mild/moderate COVID trial. Nader has already hinted that statistically significant positive results will be presented for several meaningful secondary endpoints, if not the loosely defined fever+cough at 14 days primary endpoint. Nader has repeatedly explained to bashers that Phase II trials are exploratory in the sense of looking broadly for ways (endpoints) in which the drug is efficacious, normally to be followed by more stringent Phase III re-examination of a newly selected primary endpoint. After reveal and public dissemination of these Phase II efficacy findings, which nervous nellies have doubted will ever come, will be another period of handwringing over whether FDA will be willing to grant emergency approval for statistically significant results from a small 85-person Phase II study. This handwringing should play out in our wave iv retest of $10 region to be followed by a wave v to at least $16 upon positive resolution.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.